Travers Smith LLP has advised Bridgepoint Development Capital and management shareholders on the sale of Quotient Clinical (“Quotient”), a provider of outsourced, early-stage drug development services to the global pharmaceutical industry, to GHO Capital (“GHO”) for an undisclosed sum.
Headquartered in Nottingham and employing over 280 professionals, Quotient enables pharmaceutical and biotechnology customers to improve research and development productivity, achieve significant cost savings and bring drug products to market faster.
Travers Smith’s team was led by private equity partner Helen Croke who was assisted by associates David Wall and Ed Pike. The Travers Smith team also included tax partner Simon Skinner who was assisted by tax associate Amie McFadzean.
GHO was advised by Macfarlanes.